TY - T1的重症监护室承认在多发性硬化的风险增加(P03.205) JF -神经学乔-神经病学SP - P03.205 LP - P03.205六世- 80 - 7补充AU - Ruth-Ann 首页Christine Peschken上非盟-查尔斯•伯恩斯坦盟盟-卡罗尔Hitchon盟Randy Fransoo AU -艾伦花环Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/P03.205.abstract N2 -目的:我们入住ICU的发病率相比人的女士和一个匹配的队列。背景:在重症监护病房(ICU)是昂贵的,和消费不成比例的医疗费用。对入住ICU的风险与多发性硬化症(MS)人。设计/方法:使用省级行政数据我们发现所有残疾人女士和一个年龄、性别和geographically-matched一般人群队列。2000 - 2010年,我们估计每年的发病率和入住ICU的10年累积发病率普遍的女士,我们估计入住ICU的发病率与事件队列中女士使用Cox比例风险模型调整的诊断、年龄性别、疾病和社会经济地位。结果:从2000年到2010年,入住ICU的年龄和sex-standardized年度发病率从0.51%到1.07%不等人的女士和0.36总人口的-0.60%。10年期平均年发病率在0.80%和0.45%的女士一般人群。入住ICU的原油10年累积发病率为6.03%和3.45%的女士在匹配的队列(发病率比(IRR) 1.53)。与一般人群相比,所有年龄段的入住ICU的发生率增加,但相对风险较高的人年龄18-39 3.67 (IRR)比人年龄在40岁至59岁的1.97 (IRR)和比人年龄≥60岁1.38 (IRR)。当比较事件情况下的普通人群,入住ICU在多变量Cox模型的风险增加(危险比[HR] 1.45;95%置信区间:1.19—-1.75)。结论:ICU住院的风险相对较高与女士之间的人,尤其是在年轻女士的病人。 Given the recognized adverse consequences of critical illness in the general population, future studies should determine if there are modifiable risk factors for ICU admission.Supported by: The Manitoba Health Research Council and HSC Research Foundation.Disclosure: Dr. Marrie has received research support from Sanofi-aventis. Dr. Bernstein has received personal compensation for activities with Abbott, Janssen, Vertex Pharmaceuticals, Bristol-Myers Squibb Company, Mylan Pharmaceuticals, Ranbaxy Pharmaceuticals, and Barr Pharmaceuticals. Dr. Bernstein has received research support from Abbott and Aptalis Pharma. Dr. Peschken has nothing to disclose. Dr. Hitchon has received research support from UCB Pharma. Dr. Fransoo has nothing to disclose. Dr. Garland has nothing to disclose.Tuesday, March 19 2013, 2:00 pm-6:30 pm ER -